k.brandl_de
TL3 Translator · DE · Leipzig, DE
German translation and the German regulatory picture, which is not the EU picture.
Joined 8 November 2024 · last posted 3d · groups: wiki-editors, translators, regional-eu
136Posts here
3Topics
2Solutions
970Likes received
963Likes given
32Badges
268Days visited
3.4kPosts read
Stated areas
Recent activity
Full stream-
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #13 · Compounds › Retatrutide · 25 Jul 2026 · 4 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
[2026 update] Documenting an adverse event properly Replied, post #20 · Safety › Adverse events · 24 Jul 2026 · 1 like Serious and unexpected events are the ones to document and report. Serious means hospitalization-level serious. Unexpected means not in the drug's known profile. Both…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #62 · Access › Insurance & coverage · 24 Jul 2026 · 10 likes I read post #60 twice before replying, because I had assumed the opposite. Documentation your clinician can provide: letters from clinicians describing why standard…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #106 · Analytics › Home & field testing · 20 Jul 2026 · 0 likes Why third-party testing is stronger: a home test run by the person who made the compound is a self-selected result. The test run by a neutral third party removes…
-
Why the Start Here categories exist, and what they are not for Replied, post #16 · Start Here › Welcome · 20 Jul 2026 · 1 like The FAQ link in the sidebar is maintained and worth ten hours of forum browsing. It is not comprehensive but it is well indexed for the questions that come up most.
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #101 · Sourcing › Independent verification · 18 Jul 2026 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Substitution between formats during a shortage — what changed since Replied, post #14 · Access › Shortages · 15 Jul 2026 · 10 likes Worth separating two things that post #10 runs together. Communication from suppliers: a supplier having supply problems usually communicates them. If a supplier goes…
-
Compounds this community declines to help with, and why — does this still hold? Replied, post #6 · Compounds › Other compounds · 15 Jul 2026 · 0 likes Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that…
-
Why we ask for units every single time, with three examples of what goes wrong Replied, post #127 · Start Here › How to Ask · 14 Jul 2026 · 2 likes Worth separating two things that post #123 runs together. Two things before anyone answers the substance. First, the context in the first post is clear and specific.…
-
Common supplements people ask about, assessed one at a time Replied, post #22 · Practice › Interactions · 8 Jul 2026 · 1 like Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted.…
-
What a reversed-phase purity number actually is Replied, post #34 · Analytics › HPLC & UHPLC · 8 Jul 2026 · 1 like Peak purity: a diode-array detector records a spectrum at every time point. If a peak contains two co-eluting species with different spectra, the spectrum changes…
-
Journal club: what we got wrong in an earlier session Replied, post #51 · Evidence › Journal club · 4 Jul 2026 · 17 likes SOUL (N Engl J Med 2025): Oral semaglutide cardiovascular outcomes. Extends the cardiovascular evidence to the oral formulation. Note that oral bioavailability is lower…
Maintains 5 documents
- Exenatide — referenceReview due 5 Dec 2026
- Tesamorelin — referenceReview due 21 Aug 2026
- Access notes: PolandReview due 9 May 2027
- STEP 1 — trial digestReview due 29 Sep 2026
- SURMOUNT-OSA — trial digestReview due 9 Nov 2026